Healthcare reality of the treatment of the high-risk multiple myeloma in Spain

被引：2

作者：

Hernandez-Rivas, Jose-Angel ^{[1
,2
]}

Gironella Mesa, Mercedes ^{[3
,4
]}

机构：

[1] Hosp Univ Infanta Leonor, Serv Hematol & Hemoterapia, Madrid, Spain

[2] Univ Complutense Madrid, Dept Med, Madrid, Spain

[3] Hosp Univ Vail dHebron, Serv Hematol, Barcelona, Spain

[4] Univ Autonoma Barcelona, Dept Med, Barcelona, Spain

来源：

MEDICINA CLINICA | 2020年 / 154卷 / 08期

关键词：

LENALIDOMIDE PLUS DEXAMETHASONE; TREATMENT STRATEGIES; CONSENSUS; STRATIFICATION; CARFILZOMIB; GUIDELINES; MANAGEMENT; SURVIVAL;

D O I：

10.1016/j.medcli.2019.10.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：315 / 319

页数：5

共 50 条

[31] A gene expression signature for high-risk multiple myeloma
R Kuiper
A Broyl
Y de Knegt
M H van Vliet
E H van Beers
B van der Holt
L el Jarari
G Mulligan
W Gregory
G Morgan
H Goldschmidt
H M Lokhorst
M van Duin
P Sonneveld
Leukemia, 2012, 26 : 2406 - 2413
[32] Should high-risk smouldering multiple myeloma be treated?
Richard, Shambavi
Jagannath, Sundar
Boccadoro, Mario
Mina, Roberto
LANCET HAEMATOLOGY, 2020, 7 (01): : E15 - E16
[33] A gene expression signature for high-risk multiple myeloma
Kuiper, R.
Broyl, A.
de Knegt, Y.
van Vliet, M. H.
van Beers, E. H.
van der Holt, B.
el Jarari, L.
Mulligan, G.
Gregory, W.
Morgan, G.
Goldschmidt, H.
Lokhorst, H. M.
van Duin, M.
Sonneveld, P.
LEUKEMIA, 2012, 26 (11) : 2406 - 2413
[34] Crowdsourcing a High-Risk Classifier for Multiple Myeloma Patients
Dervan, Andrew P.
Mason, Michael
Towfic, Fadi
Amatangelo, Michael
Auclair, Daniel
Bassett, Douglas
Dai, Hongyue
Dalton, William S.
Danziger, Samuel
Flynt, Erin
Goldschmidt, Hartmut
Guinney, Justin
Hose, Dirk
Mavrommatis, Konstantimos
Morgan, Gareth J.
Munshi, Nikhil
Ratushny, Alexander
Rozelle, Dan
Samur, Mehmet Kemal
Schmitz, Frank
Shain, Kenneth H.
Trotter, Matthew
Walker, Brian A.
White, Brian S.
Yu, Thomas
Thakurta, Anjan
BLOOD, 2017, 130
[35] Dysregulation of Cellular Immunity in High-Risk Multiple Myeloma
Bekri, Selma
Katz, Simone
Kelly, Geoffrey
Dawson, Travis
D'Souza, Darwin
Mason, Michael
Alloy, Alexandre
Biswas, Shameek
Kim-Schulze, Seunghee
Gnjatic, Sacha
Parekh, Samir
Jagannath, Sundar
Lagana, Alessandro
Cho, Hearn Jay
BLOOD, 2023, 142
[36] Drug response prediction in high-risk multiple myeloma
Vangsted, A. J.
Helm-Petersen, S.
Cowland, J. B.
Jensen, P. B.
Gimsing, P.
Barlogie, B.
Knudsen, S.
GENE, 2018, 644 : 80 - 86
[37] How I treat high-risk multiple myeloma
Zamagni, Elena
Barbato, Simona
Cavo, Michele
BLOOD, 2022, 139 (19) : 2889 - 2903
[38] Genomic analysis of high-risk smoldering multiple myeloma
Lopez-Corral, Lucia
Victoria Mateos, Maria
Corchete, Luis A.
Eugenia Sarasquete, Maria
de la Rubia, Javier
de Arriba, Felipe
Lahuerta, Juan-Jose
Garcia-Sanz, Ramon
San Miguel, Jesus F.
Gutierrez, Norma C.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (09): : 1439 - 1443
[39] Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
Leypoldt, Lisa B.
Tichy, Diana
Besemer, Britta
Haenel, Mathias
Raab, Marc S.
Mann, Christoph
Munder, Markus
Reinhardt, Hans Christian
Nogai, Axel
Goerner, Martin
Ko, Yon-Dschun
de Wit, Maike
Salwender, Hans
Scheid, Christof
Graeven, Ullrich
Peceny, Rudolf
Staib, Peter
Dieing, Annette
Einsele, Hermann
Jauch, Anna
Hundemer, Michael
Zago, Manola
Pozek, Ema
Benner, Axel
Bokemeyer, Carsten
Goldschmidt, Hartmut
Weisel, Katja C.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (01) : 26 - +
[40] Revisiting treatment paradigms in high-risk smoldering multiple myeloma: out with the old, in with the new?
Ghobrial, Irene M.
LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2328 - 2330

← 1 2 3 4 5 →